4,086 Shares in Haemonetics Co. (NYSE:HAE) Acquired by Empowered Funds LLC

Empowered Funds LLC acquired a new position in shares of Haemonetics Co. (NYSE:HAE) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 4,086 shares of the medical instruments supplier’s stock, valued at approximately $319,000.

A number of other institutional investors have also recently made changes to their positions in the business. Riverwater Partners LLC grew its stake in Haemonetics by 185.0% during the 3rd quarter. Riverwater Partners LLC now owns 44,841 shares of the medical instruments supplier’s stock valued at $3,556,000 after purchasing an additional 29,109 shares during the last quarter. Keene & Associates Inc. grew its stake in shares of Haemonetics by 3.0% in the third quarter. Keene & Associates Inc. now owns 10,174 shares of the medical instruments supplier’s stock worth $818,000 after acquiring an additional 298 shares in the last quarter. CWC Advisors LLC. acquired a new position in shares of Haemonetics in the 3rd quarter valued at $231,000. Boston Trust Walden Corp lifted its holdings in shares of Haemonetics by 13.8% in the 3rd quarter. Boston Trust Walden Corp now owns 809,608 shares of the medical instruments supplier’s stock valued at $65,076,000 after purchasing an additional 98,019 shares during the last quarter. Finally, State of Alaska Department of Revenue grew its position in shares of Haemonetics by 7.3% during the third quarter. State of Alaska Department of Revenue now owns 5,880 shares of the medical instruments supplier’s stock worth $472,000 after acquiring an additional 400 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Stock Performance

HAE stock opened at $63.36 on Friday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The stock’s fifty day moving average is $72.98 and its two-hundred day moving average is $76.76. The stock has a market capitalization of $3.18 billion, a price-to-earnings ratio of 24.95, a PEG ratio of 1.12 and a beta of 0.39. Haemonetics Co. has a 1 year low of $58.80 and a 1 year high of $97.97.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, research analysts predict that Haemonetics Co. will post 4.55 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Bank of America cut Haemonetics from a “neutral” rating to an “underperform” rating and decreased their price objective for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. Barrington Research cut their price target on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Raymond James reiterated a “strong-buy” rating and issued a $115.00 price target (down from $120.00) on shares of Haemonetics in a report on Friday, February 7th. JMP Securities cut their price objective on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a report on Friday, February 7th. Finally, StockNews.com lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $101.67.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.